Shouyao Holdings prepares and tests new Mat2A inhibitors for cancer
Oct. 30, 2023
S-Adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors have been described in a Shouyao Holdings (Beijing) Co. Ltd. patent to be useful for the treatment of cancer.
